HealthDay News — For patients with systemic lupus erythematosus (SLE), obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody, is superior to placebo, according to a study published ...

Prasad's stint included several controversial vaccine decisions; the FDA is now searching for a new head for its vaccine division.

Cerebral folate deficiency is a rare neurological disorder characterized by a decrease in CSF folate levels, leading to developmental regression, seizures, movement disorders, and other neurological ...

A Prescription Drug User Fee Act target date of December 22, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

Findings seen in pilot study of older adults with mild cognitive impairment, but other coprimary outcomes did not meet significance thresholds.

The approval was based on data from the POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of ...

Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.

In addition, GLP-1 receptor agonist initiation linked to reduced risks for SUD-related adverse events for people with preexisting SUD.

Povetacicept significantly reduced proteinuria in patients with IgA nephropathy in the RAINIER trial, supporting an upcoming FDA submission.

Cure rate of 42% estimated in cure modeling; highest rate seen for patients with low Follicular Lymphoma International Prognostic Index scores.

HealthDay News — US Health Secretary Robert F. Kennedy Jr. announced a new effort Thursday aimed at getting medical schools to spend more time teaching students about nutrition. Federal officials say ...

Tazverik is withdrawn for all indications, including follicular lymphoma and epithelioid sarcoma, following unfavorable trial safety data.